Quarterly report pursuant to Section 13 or 15(d)

ASSET ACQUISITION (Details)

v3.22.1
ASSET ACQUISITION (Details)
$ in Millions
 1 Months Ended 3 Months Ended
Jan. 31, 2022
USD ($)
item
Mar. 31, 2022
item
Asset Acquisition [Line Items]    
Number of branded drugs in product portfolio | item 9 9
VYNE Product Acquisition    
Asset Acquisition [Line Items]    
Upfront payment $ 20.0  
Additional payment 5.0  
One-time payment $ 450.0  
Percentage of upfront payment received 10.00%  
VYNE Product Acquisition | If Annual Sales Reaches To 100 Million    
Asset Acquisition [Line Items]    
Annual sales $ 100.0  
One-time payment 10.0  
VYNE Product Acquisition | If Annual Sales Reaches To 200 Million    
Asset Acquisition [Line Items]    
Annual sales 200.0  
One-time payment 20.0  
VYNE Product Acquisition | If Annual Sales Reaches To 300 Million    
Asset Acquisition [Line Items]    
Annual sales 300.0  
One-time payment 30.0  
VYNE Product Acquisition | If Annual Sales Reaches To 400 Million    
Asset Acquisition [Line Items]    
Annual sales 400.0  
One-time payment 40.0  
VYNE Product Acquisition | If Annual Sales Reaches To 500 Million    
Asset Acquisition [Line Items]    
Annual sales 500.0  
One-time payment $ 50.0  
Minocycline Products    
Asset Acquisition [Line Items]    
Business Acquisition interest 4.00%  
Molecule Stabilizing Technology    
Asset Acquisition [Line Items]    
Business Acquisition interest 1.50%